RED Full risk-off day.
Cash is a position
Regime: RED
The Picks
| Ticker | Scan Price | Gap % | RVOL | Catalyst | ML Hold Prob | ML Expected |
|---|---|---|---|---|---|---|
| ABT | $100.00 | 12.02 | 32.09 | Analyst: RBC Capital reiterated Outperform rating with $130 price target, and multiple analysts provided bullish forecasts for Abbott. | — | — |
| PLD | $150.50 | 4.94 | 20.51 | Earnings: Prologis Q2 2026 earnings call combined with AI-driven warehouse demand thesis and analyst price target increase to $156 from Barclays. | — | — |
| MO | $74.09 | 5.06 | 18.84 | Earnings: Altria Group topped Q1 earnings estimates as higher pricing offset volume declines, driving early trading gains [via web] | — | — |
| BTI | $62.63 | 6.64 | 26.03 | No catalyst identified | — | — |
| MRK | $128.79 | 4.19 | 17.09 | Fda: FDA approved Merck's LIPFENDRA (bempedoic acid) tablets as an adjunct therapy to reduce LDL cholesterol in adults with hypercholesterolemia, expanding the company's cardiovascular portfolio. | — | — |
The Results
| Ticker | Entry | Entry Time | Exit | Exit Time | Method | P/L | % | Catalyst |
|---|---|---|---|---|---|---|---|---|
| ABT | $100.00 | $99.81 | 3:20 PM | Shadow | $-19.50 | -0.19 | Analyst: RBC Capital reiterated Outperform rating with $130 price target, and multiple analysts provided bullish forecasts for Abbott. | |
| PLD | $150.50 | $148.81 | 3:20 PM | Shadow | $-111.54 | -1.12 | Earnings: Prologis Q2 2026 earnings call combined with AI-driven warehouse demand thesis and analyst price target increase to $156 from Barclays. | |
| MO | $74.09 | $74.25 | 3:20 PM | Shadow | $21.44 | 0.22 | Earnings: Altria Group topped Q1 earnings estimates as higher pricing offset volume declines, driving early trading gains [via web] | |
| BTI | $62.63 | $62.41 | 3:20 PM | Shadow | $-34.98 | -0.35 | No catalyst identified | |
| MRK | $128.79 | $127.36 | 3:20 PM | Shadow | $-110.49 | -1.11 | Fda: FDA approved Merck's LIPFENDRA (bempedoic acid) tablets as an adjunct therapy to reduce LDL cholesterol in adults with hypercholesterolemia, expanding the company's cardiovascular portfolio. |
Shadow Results
| Ticker | Shadow Entry | Shadow Exit | Exit Time | Method | Shadow P/L | % | Result | Catalyst |
|---|---|---|---|---|---|---|---|---|
| ABT | $100.00 | $99.81 | 3:20 PM | Shadow | $-19.50 | -0.19 | LOSS | Analyst: RBC Capital reiterated Outperform rating with $130 price target, and multiple analysts provided bullish forecasts for Abbott. |
| PLD | $150.50 | $148.81 | 3:20 PM | Shadow | $-111.54 | -1.12 | LOSS | Earnings: Prologis Q2 2026 earnings call combined with AI-driven warehouse demand thesis and analyst price target increase to $156 from Barclays. |
| MO | $74.09 | $74.25 | 3:20 PM | Shadow | $21.44 | 0.22 | WIN | Earnings: Altria Group topped Q1 earnings estimates as higher pricing offset volume declines, driving early trading gains [via web] |
| BTI | $62.63 | $62.41 | 3:20 PM | Shadow | $-34.98 | -0.35 | LOSS | No catalyst identified |
| MRK | $128.79 | $127.36 | 3:20 PM | Shadow | $-110.49 | -1.11 | LOSS | Fda: FDA approved Merck's LIPFENDRA (bempedoic acid) tablets as an adjunct therapy to reduce LDL cholesterol in adults with hypercholesterolemia, expanding the company's cardiovascular portfolio. |
Things to Explore
Interested in our research, validation methodology, and trading system?
Get in TouchWork With Diana
Need a context architect to scaffold your AI agents and facilitate structured learning?
Visit goddev.aiThis post is part of a series documenting MorningEdge's development in real time. The knowledge base contains 0 books, papers, and lab reports totaling 0+ searchable chunks. The trading system described is paper trading only — no real capital is at risk.